BridgeMD
New treatment option for Cutaneous Basal Cell Carcinoma
Official title Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
ClinicalTrials.gov ID: NCT07251413
What this study is testing
What is cemiplimab?
cemiplimab is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for cutaneous basal cell carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Basal cutaneous cell carcinoma (BCC) is the most common skin cancer. Early-stage disease is managed with surgery or radiation that cure more than 95% of patients.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male/female participants who are at least 18 years of age on the day of signing informed consent.
- Histologically confirmed diagnosis of basal cell carcinoma (BCC), potentially resectable with curative intention.
- The definition of resectability will be determined locally by the surgeon according to his/her criteria and local standard guidelines. The validated...
- Surgery would be recommended in routine clinical practice.
- Patient should be considered as high risk, defined as:
You likely can't join if
- Distant metastatic disease (M1), visceral and/or distant nodal.
- Patients who have another malignancy that is progressing or requires active treatment, except:
- Non-melanoma skin cancer that has undergone potentially curative therapy In situ cervical carcinoma
- Any tumor that has been deemed to be effectively treated with definitive local control (with or without continued adjuvant hormonal therapy).
- Patients who have received a previous systemic treatment for cancer within the last previous 3 months or 5 half-lives (whichever is latest)...
- History of, or significant evidence of risk for, severe chronic inflammatory or autoimmune disease. Note: Patients with vitiligo, type I diabetes...
See the full eligibility criteria
Who can join
- Male/female participants who are at least 18 years of age on the day of signing informed consent.
- Histologically confirmed diagnosis of basal cell carcinoma (BCC), potentially resectable with curative intention.
- The definition of resectability will be determined locally by the surgeon according to his/her criteria and local standard guidelines. The validated classification from University Hospital of Lille should be used for...
- Surgery would be recommended in routine clinical practice.
- Patient should be considered as high risk, defined as:
- at least 1 large lesion (≥ 2 cm in diameter in trunk/extremities or any size in Head, neck, hands, feet, pretibial, and anogenital) still resectable, but with increased risk for cosmetic disfigurement or functional...
- Having basosquamous, infiltrative, sclerosing/morpheaform, micronodular, and BCC with carcinosarcomatous differentiation features in any portion of the tumor.
- Patients with large (≥ 3 cm in diameter in areas of intermedium risk of recurrence such as forehead, cheek, chin, neck, scalp or ≥ 5 cm for lesions in trunk/extremities) recurrent basal cell carcinoma are also eligible.
- Multicentric tumors that would require a cosmetic disfigurement or functional defects by assessment of the enrolling physician will be eligible.
- At least one measurable lesion by RECIST v1.1 (Appendix 3).
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- Life expectancy of at least 24 weeks.
- Pretreatment tumor tissue sample available. Note: If the biopsy is considered by the investigator to pose an unacceptable safety risk to the patient or would compromise tumor measurements, the biopsy requirement may be...
- Adequate normal organ and marrow function as defined below:
- Absolute neutrophil count ≥ 1.5 x 109 cells/L
- Platelets ≥ 75 x 109/L
- Hemoglobin ≥ 8 g/dL
- Aspartate and alanine aminotransferases (AST, ALT) ≤ 3 x upper limit of normal (ULN) and alkaline phosphatase \<2.5x ULN
- Thyroid stimulating hormone (TSH) within normal limits, or Total triiodothyronine (T3) is within normal limits, or Free T3 and free thyroxine (T4) are within the normal limits
- Total bilirubin ≤ 2 x ULN (except patients with documented Gilbert's syndrome; up to 3 x ULN)
- Creatinine \ 60)
- Female patients of childbearing potential (WOCBP) must provide a negative urine pregnancy test 72 hours prior to the first administration of study treatment, and must agree to: (I) use a medically accepted and highly...
- Amenorrheic for ≥1 year in the absence of chemotherapy and/or hormonal treatments
- Luteinizing hormone (LH) and/or follicle stimulating hormone and/or estradiol levels in the postmenopausal range
- Radiation induced oophorectomy with last menses \>1 year ago
- Chemotherapy induced menopause with \>1 year interval since last menses
- Surgical sterilization (bilateral oophorectomy or hysterectomy)
- Women \<50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and...
- Women ≥50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, or underwent surgical sterilization (bilateral...
- Male participants of reproductive potential are eligible to participate if they agree to the following starting with the first dose of study treatment through at least 180 days (a spermatogenesis cycle) after the last...
- Refrain from donating sperm plus, either:
- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent, or
- Must agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception, as a condom may break or leak, when having sexual intercourse with a...
What rules you out
- Distant metastatic disease (M1), visceral and/or distant nodal.
- Patients who have another malignancy that is progressing or requires active treatment, except:
- Non-melanoma skin cancer that has undergone potentially curative therapy In situ cervical carcinoma
- Any tumor that has been deemed to be effectively treated with definitive local control (with or without continued adjuvant hormonal therapy).
- Patients who have received a previous systemic treatment for cancer within the last previous 3 months or 5 half-lives (whichever is latest), including immunotherapy, prior to initiation of dosing within this protocol.
- History of, or significant evidence of risk for, severe chronic inflammatory or autoimmune disease. Note: Patients with vitiligo, type I diabetes mellitus, and endocrinopathies (including hypothyroidism due to...
- Patients who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization...
- Patients with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of...
- Patients with known HIV who have controlled infection (undetectable viral load and CD4 count above 100 on a stable antiviral regimen) are permitted. For patients with controlled HIV infection, monitoring will be...
- Active tuberculosis.
- Receipt of a live vaccine within 28 days of enrollment.
- Prior allogeneic stem cell transplantation, or autologous stem cell transplantation.
- Recipient of a solid organ transplant (other than corneal transplants).
- History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.
- Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 2 weeks prior to enrollment. Notes: Physiologic replacement...
- Has participated in a study of an investigational agent or an investigational device within 4 weeks of enrollment.
- Dementia or significantly altered mental status, or any social or economic conditions that would prohibit or interfere with the understanding or rendering of informed consent and compliance with the requirements of this...
- Female patients who are pregnant or breast-feeding.
The study team makes the final eligibility decision.
Where it's taking place
- Barcelona, Barcelona, Spain
- Madrid, Madrid, Spain
- Zaragoza, Zaragoza, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Barcelona, Barcelona, Spain; Madrid, Madrid, Spain; Zaragoza, Zaragoza, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.